Harmony Biosciences To Highlight New Open-Label Extension Data From Its Investigation Of EPX-100 In Ongoing Phase 3 ARGUS Trial For Treatment Of Dravet Syndrome At 2025 AES Annual Meeting

Benzinga · 3d ago

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that it will highlight new open-label extension data from the company's investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS trial for the treatment of Dravet syndrome at the 2025 American Epilepsy Society (AES) Annual Meeting being held December 5 – December 9, 2025, in Atlanta, GA.

The ARGUS trial is currently enrolling, and more information can be found at argustrial.com.